Allergen-specific immunotherapy in asthmatic children: from the basis to clinical applications

References

• Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59(5), 469–478 (2004).
   PubMed Web of Science ®Google Scholar
• Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 31(1), 143–178 (2008).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Intrinsic asthma: not so different from allergic asthma but driven by superantigens? Clin. Exp. Allergy 39(8), 1145–1151 (2009).
   PubMed Web of Science ®Google Scholar
• He XY, Simpson JL, Wang F. Inflammatory phenotypes in stable and acute childhood asthma. Paediatr. Respir. Rev. 12(3), 165–169 (2011).
   PubMed Web of Science ®Google Scholar
• Cox L, Esch RE, Corbett M, Hankin C, Nelson M, Plunkett G. Allergen immunotherapy practice in the United States: guidelines, measures, and outcomes. Ann. Allergy Asthma Immunol. 107(4), 289–299; quiz 300 (2011).
   PubMed Web of Science ®Google Scholar
• WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Arerugi 47(7), 698–704 (1998).
   Google Scholar
• Noon L. Prophylactic inoculation against hay fever. The Lancet 177(4580), 1572–1573 (1911).
   Google Scholar
• Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J. Allergy Clin. Immunol. 127(1), 30–38 (2011).
   PubMed Web of Science ®Google Scholar
• Viswanathan RK, Busse WW. Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses. Chest 141(5), 1303–1314 (2012).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Michel FB. Specific immunotherapy in asthma: is it effective? J. Allergy Clin. Immunol. 94(1), 1–11 (1994).
   PubMed Web of Science ®Google Scholar
• Compalati E, Rogkakou A, Passalacqua G, Canonica GW. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review. Curr. Opin. Allergy Clin. Immunol. 12(4), 427–433 (2012).
   PubMed Web of Science ®Google Scholar
• Mousallem T, Burks AW. Immunology in the Clinic Review Series; focus on allergies: immunotherapy for food allergy. Clin. Exp. Immunol. 167(1), 26–31 (2012).
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 8, CD001186 (2010).
   Google Scholar
• Rodríguez-Pérez N, Penagos M, Portnoy JM. New types of immunotherapy in children. Curr. Allergy Asthma Rep. 8(6), 484–492 (2008).
   Google Scholar
• Vovolis V, Kalogiros L, Mitsias D, Sifnaios E. Severe repeated anaphylactic reactions to sublingual immunotherapy. Allergol. Immunopathol. (Madr.) doi:10.1016/j.aller.2012.05.012 (2012) (Epub ahead of print).
   Google Scholar
• Des Roches A, Paradis L, Menardo JL, Bouges S, Daurés JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol. 99(4), 450–453 (1997).
   PubMed Web of Science ®Google Scholar
• Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J. Investig. Allergol. Clin. Immunol. 17(2), 85–91 (2007).
   PubMed Web of Science ®Google Scholar
• Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy 31(9), 1392–1397 (2001).
   PubMed Web of Science ®Google Scholar
• Harmanci K, Razi CH, Toyran M, Kanmaz G, Cengizlier MR. Evaluation of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. Asian Pac. J. Allergy Immunol. 28(1), 7–13 (2010).
   PubMedGoogle Scholar
• Rak S, Yang WH, Pedersen MR, Durham SR. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual. Life Res. 16(2), 191–201 (2007).
   PubMed Web of Science ®Google Scholar
• Frew AJ. Allergen immunotherapy. J. Allergy Clin. Immunol. 125(2 Suppl. 2), S306–S313 (2010).
   PubMed Web of Science ®Google Scholar
• Jacobsen L, Wahn U, Bilo MB. Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit – the centenary of allergen specific subcutaneous immunotherapy. Clin. Transl. Allergy 2, 8 (2012).
   Google Scholar
• Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 114(4), 851–857 (2004).
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17(1), 1–12 (1996).
   PubMedGoogle Scholar
• Holt PG, Rowe J, Kusel M et al. Toward improved prediction of risk for atopy and asthma among preschoolers: a prospective cohort study. J. Allergy Clin. Immunol. 125(3), 653–659, 659.e1 (2010).
   PubMed Web of Science ®Google Scholar
• Sly PD, Boner AL, Björksten B et al. Early identification of atopy in the prediction of persistent asthma in children. Lancet 372(9643), 1100–1106 (2008).
   PubMed Web of Science ®Google Scholar
• Stein RT, Sherrill D, Morgan WJ et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354(9178), 541–545 (1999).
   PubMed Web of Science ®Google Scholar
• Martinez FD. What have we learned from the Tucson Children’s Respiratory Study? Paediatr. Respir. Rev. 3(3), 193–197 (2002).
   PubMedGoogle Scholar
• Holt PG, Strickland DH, Bosco A, Jahnsen FL. Pathogenic mechanisms of allergic inflammation: atopic asthma as a paradigm. Adv. Immunol. 104, 51–113 (2009).
   Google Scholar
• Wei B, Zhang H, Li L, Li M, Shang Y. T helper 17 cells and regulatory T-cell imbalance in paediatric patients with asthma. J. Int. Med. Res. 39(4), 1293–1305 (2011).
   Google Scholar
• Perkins C, Yanase N, Smulian G et al. Selective stimulation of IL-4 receptor on smooth muscle induces airway hyperresponsiveness in mice. J. Exp. Med. 208(4), 853–867 (2011).
   Google Scholar
• Kuperman DA, Schleimer RP. Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr. Mol. Med. 8(5), 384–392 (2008).
   PubMed Web of Science ®Google Scholar
• Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 113(6), 1025–1034; quiz 1035 (2004).
   PubMed Web of Science ®Google Scholar
• Hall G, Lund L, Lamb JR, Jarman ER. Kinetics and mode of peptide delivery via the respiratory mucosa determine the outcome of activation versus Th2 immunity in allergic inflammation of the airways. J. Allergy Clin. Immunol. 110(6), 883–890 (2002).
   PubMedGoogle Scholar
• von Hertzen LC, Savolainen J, Hannuksela M et al. Scientific rationale for the Finnish Allergy Programme 2008–2018: emphasis on prevention and endorsing tolerance. Allergy 64(5), 678–701 (2009).
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J. Allergy Clin. Immunol. 123(4), 735–746; quiz 747 (2009).
   PubMed Web of Science ®Google Scholar
• Maggi E, Vultaggio A, Matucci A. T-cell responses during allergen-specific immunotherapy. Curr. Opin. Allergy Clin. Immunol. 12(1), 1–6 (2012).
   PubMed Web of Science ®Google Scholar
• Maggi E. T-cell responses induced by allergen-specific immunotherapy. Clin. Exp. Immunol. 161(1), 10–18 (2010).
   PubMed Web of Science ®Google Scholar
• Ippoliti F, De Santis W, Volterrani A et al. Immunomodulation during sublingual therapy in allergic children. Pediatr. Allergy Immunol. 14(3), 216–221 (2003).
   PubMed Web of Science ®Google Scholar
• Vissers JL, van Esch BC, Hofman GA, Kapsenberg ML, Weller FR, van Oosterhout AJ. Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model. J. Allergy Clin. Immunol. 113(6), 1204–1210 (2004).
   PubMed Web of Science ®Google Scholar
• Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. 111(6), 1255–1261 (2003).
   PubMed Web of Science ®Google Scholar
• Jutel M, Akdis M, Budak F et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33(5), 1205–1214 (2003).
   PubMed Web of Science ®Google Scholar
• Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J. Allergy Clin. Immunol. 127(2), 502–508.e1 (2011).
   PubMed Web of Science ®Google Scholar
• Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J. Allergy Clin. Immunol. 117(2), 263–268 (2006).
   PubMed Web of Science ®Google Scholar
• Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J. Allergy Clin. Immunol. 126(5), 942–949 (2010).
   PubMed Web of Science ®Google Scholar
• Yuan HC, Wu KG, Chen CJ et al. Mapping of IgE and IgG4 antibody-binding epitopes in Cyn d 1, the major allergen of Bermuda grass pollen. Int. Arch. Allergy Immunol. 157(2), 125–135 (2012).
   Google Scholar
• Fujita H, Meyer N, Akdis M, Akdis CA. Mechanisms of immune tolerance to allergens. Chem. Immunol. Allergy 96, 30–38 (2012).
   PubMedGoogle Scholar
• Pilette C, Nouri-Aria KT, Jacobson MR et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J. Immunol. 178(7), 4658–4666 (2007).
   PubMed Web of Science ®Google Scholar
• Akkoc T, Akdis M, Akdis CA. Update in the mechanisms of allergen-specific immunotheraphy. Allergy. Asthma Immunol. Res. 3(1), 11–20 (2011).
   PubMed Web of Science ®Google Scholar
• Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy 66(6), 725–732 (2011).
   PubMed Web of Science ®Google Scholar
• Cappella A, Durham SR. Allergen immunotherapy for allergic respiratory diseases. Hum. Vaccin. Immunother. 8(10), 1499–1512 (2012).
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 127(1), 18–27; quiz 28 (2011).
   PubMed Web of Science ®Google Scholar
• Basomba A, Tabar AI, de Rojas DH et al. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. J. Allergy Clin. Immunol. 109(6), 943–948 (2002).
   PubMed Web of Science ®Google Scholar
• Sicherer SH, Wood RA; American Academy of Pediatrics Section on Allergy and Immunology. Allergy testing in childhood: using allergen-specific IgE tests. Pediatrics 129(1), 193–197 (2012).
   Google Scholar
• Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J. Allergy Clin. Immunol. 123(4), 763–769 (2009).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Hejjaoui A, Becker WM et al. Clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. I. Clinical and immunologic characteristics. J. Allergy Clin. Immunol. 87(3), 737–746 (1991).
   Google Scholar
• Bousquet J, Becker WM, Hejjaoui A et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J. Allergy Clin. Immunol. 88(1), 43–53 (1991).
   PubMed Web of Science ®Google Scholar
• Adkinson NF Jr, Eggleston PA, Eney D et al. A controlled trial of immunotherapy for asthma in allergic children. N. Engl. J. Med. 336(5), 324–331 (1997).
   PubMed Web of Science ®Google Scholar
• Hedlin G, Wille S, Browaldh L et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J. Allergy Clin. Immunol. 103(4), 609–614 (1999).
   Google Scholar
• Calderón MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J. Allergy Clin. Immunol. 129(4), 929–934 (2012).
   PubMed Web of Science ®Google Scholar
• Bufe A, Ziegler-Kirbach E, Stoeckmann E et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 59(5), 498–504 (2004).
   PubMed Web of Science ®Google Scholar
• Rolinck-Werninghaus C, Wolf H, Liebke C et al. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 59(12), 1285–1293 (2004).
   PubMed Web of Science ®Google Scholar
• Valovirta E, Jacobsen L, Ljørring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 61(10), 1177–1183 (2006).
   PubMed Web of Science ®Google Scholar
• Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A; Study Group. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 60(6), 801–807 (2005).
   PubMed Web of Science ®Google Scholar
• Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin. Exp. Allergy 39(3), 401–408 (2009).
   PubMed Web of Science ®Google Scholar
• Wessel F, Chartier A, Meunier JP, Magnan A. Safety and tolerability of an SQ-standardized grass allergy immunotherapy tablet (Grazax®) in a real-life setting for three consecutive seasons - the GRAAL trial. Clin. Drug Investig. 32(7), 451–463 (2012).
   PubMed Web of Science ®Google Scholar
• Bufe A, Eberle P, Franke-Beckmann E et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J. Allergy Clin. Immunol. 123(1), 167–173.e7 (2009).
   PubMed Web of Science ®Google Scholar
• Ibañez MD, Kaiser F, Knecht R et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr. Allergy Immunol. 18(6), 516–522 (2007).
   PubMed Web of Science ®Google Scholar
• Röder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J. Allergy Clin. Immunol. 119(4), 892–898 (2007).
   PubMed Web of Science ®Google Scholar
• Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J. Allergy Clin. Immunol. 127(1), 64–71, 71.e1 (2011).
   PubMed Web of Science ®Google Scholar
• Mösges R, Graute V, Christ H, Sieber HJ, Wahn U, Niggemann B. Safety of ultra-rush titration of sublingual immunotherapy in asthmatic children with tree-pollen allergy. Pediatr. Allergy Immunol. 21(8), 1135–1138 (2010).
   PubMed Web of Science ®Google Scholar
• Caffarelli C, Sensi LG, Marcucci F, Cavagni G. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 55(12), 1142–1147 (2000).
   PubMed Web of Science ®Google Scholar
• Pajno GB, Caminiti L, Crisafulli G et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr. Allergy Immunol. 22(8), 803–807 (2011).
   PubMed Web of Science ®Google Scholar
• Stelmach I, Kaluzinska-Parzyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy 67(3), 312–320 (2012).
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy for allergic rhinitis: an update. Curr. Opin. Otolaryngol. Head Neck Surg. 19(1), 43–47 (2011).
   Google Scholar
• Larenas-Linnemann DE, Pietropaolo-Cienfuegos DR, Calderón MA. Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward. Ann. Allergy Asthma Immunol. 107(5), 407–416.e11 (2011).
   PubMedGoogle Scholar
• Penagos M, Passalacqua G, Compalati E et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 133(3), 599–609 (2008).
   PubMed Web of Science ®Google Scholar
• Portnoy JM. Immunotherapy for asthma: unfavorable studies. Ann. Allergy Asthma Immunol. 87(1 Suppl. 1), 28–32 (2001).
   Google Scholar
• Ibero M, Castillo MJ. Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of Dermatophagoides pteronyssinus. J. Investig. Allergol. Clin. Immunol. 16(3), 194–202 (2006).
   Web of Science ®Google Scholar
• Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr. Allergy Immunol. 17(6), 408–415 (2006).
   PubMed Web of Science ®Google Scholar
• Maestrelli P, Zanolla L, Pozzan M, Fabbri LM; Regione Veneto Study Group on the ‘Effect of immunotherapy in allergic asthma’. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J. Allergy Clin. Immunol. 113(4), 643–649 (2004).
   PubMed Web of Science ®Google Scholar
• Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 55(9), 842–849 (2000).
   PubMed Web of Science ®Google Scholar
• Tsai TC, Lu JH, Chen SJ, Tang RB. Clinical efficacy of house dust mite-specific immunotherapy in asthmatic children. Pediatr. Neonatol. 51(1), 14–18 (2010).
   PubMed Web of Science ®Google Scholar
• Pifferi M, Baldini G, Marrazzini G et al. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy 57(9), 785–790 (2002).
   PubMed Web of Science ®Google Scholar
• Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir. Med. 100(8), 1374–1383 (2006).
   PubMed Web of Science ®Google Scholar
• Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr. Allergy Immunol. 18(1), 47–57 (2007).
   PubMed Web of Science ®Google Scholar
• Eifan AO, Akkoc T, Yildiz A et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin. Exp. Allergy 40(6), 922–932 (2010).
   PubMed Web of Science ®Google Scholar
• Sundin B, Lilja G, Graff-Lonnevig V et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J. Allergy Clin. Immunol. 77(3), 478–487 (1986).
   Google Scholar
• Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. I. Clinical results. Allergy 47(3), 249–254 (1992).
   Google Scholar
• Alvarez-Cuesta E, Berges-Gimeno P, González-Mancebo E et al. Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study. Allergy 62(7), 810–817 (2007).
   Google Scholar
• Lin YC, Su HJ, Hsiue TR, Lee CH, Chen CW, Guo YL. Levels of house dust mite-specific IgE and cockroach-specific IgE and their association with lower pulmonary function in Taiwanese children. Chest 121(2), 347–353 (2002).
   PubMedGoogle Scholar
• Perzanowski MS, Rönmark E, Nold B, Lundbäck B, Platts-Mills TA. Relevance of allergens from cats and dogs to asthma in the northernmost province of Sweden: schools as a major site of exposure. J. Allergy Clin. Immunol. 103(6), 1018–1024 (1999).
   PubMed Web of Science ®Google Scholar
• Gassner-Bachmann M, Wüthrich B. Farmers’ children suffer less from hay fever and asthma. Dtsch. Med. Wochenschr. 125(31-32), 924–931 (2000).
   PubMed Web of Science ®Google Scholar
• Van Gysel D, Govaere E, Doli E, De Baets F. Cockroach sensitisation in Belgian children. Eur. J. Pediatr. 165(9), 662–664 (2006).
   Google Scholar
• Srivastava D, Gaur SN, Arora N, Singh BP. Clinico-immunological changes post-immunotherapy with Periplaneta americana. Eur. J. Clin. Invest. 41(8), 879–888 (2011).
   Google Scholar
• Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J. Allergy Clin. Immunol. 85(2), 460–472 (1990).
   PubMed Web of Science ®Google Scholar
• Malling HJ, Stahl Skov P. Diagnosis and immunotherapy of mould allergy. VIII. Qualitative and quantitative estimation of IgE in Cladosporium immunotherapy. Allergy 43(3), 228–238 (1988).
   Google Scholar
• Tabar AI, Lizaso MT, García BE et al. Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety. Pediatr. Allergy Immunol. 19(1), 67–75 (2008).
   Google Scholar
• Kiliç M, Altintas DU, Yilmaz M, Bingöl-Karakoç G, Burgut R, Güneser-Kendirli S. Evaluation of efficacy of immunotherapy in children with asthma monosensitized to Alternaria. Turk. J. Pediatr. 53(3), 285–294 (2011).
   Google Scholar
• Ward GW Jr, Karlsson G, Rose G, Platts-Mills TA. Trichophyton asthma: sensitisation of bronchi and upper airways to dermatophyte antigen. Lancet 1(8643), 859–862 (1989).
   PubMed Web of Science ®Google Scholar
• Cao LF, Lu Q, Gu HL et al. Clinical evaluation for sublingual immunotherapy of allergic asthma and atopic rhinitis with Dermatophagoides farinae drops. Zhonghua Er Ke Za Zhi 45(10), 736–741 (2007).
   PubMedGoogle Scholar
• Bahçeciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr. Pulmonol. 32(1), 49–55 (2001).
   PubMed Web of Science ®Google Scholar
• Marcucci F, Sensi L, Frati F et al. Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy 58(7), 657–662 (2003).
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Guerra L, Pasquali M, Lombardi C, Canonica GW. Efficacy and safety of sublingual immunotherapy. Ann. Allergy Asthma Immunol. 93(1), 3–12; quiz 12 (2004).
   PubMed Web of Science ®Google Scholar
• Keles S, Karakoc-Aydiner E, Ozen A et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J. Allergy Clin. Immunol. 128(4), 808–815.e7 (2011).
   PubMed Web of Science ®Google Scholar
• Calderon MA, Demoly P, Gerth van Wijk R et al. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin. Transl. Allergy 2(1), 20 (2012).
   PubMedGoogle Scholar
• Marseglia GL, Incorvaia C, La Rosa M, Frati F, Marcucci F. Sublingual immunotherapy in children: facts and needs. Ital. J. Pediatr. 35(1), 31 (2009).
   PubMedGoogle Scholar
• Olaguíbel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J. Investig. Allergol. Clin. Immunol. 15(1), 9–16 (2005).
   PubMed Web of Science ®Google Scholar
• Di Bona D, Plaia A, Leto-Barone MS et al. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J. Allergy Clin. Immunol. 130(5), 1097–1107 (2012).
   PubMed Web of Science ®Google Scholar
• Larenas Linnemann DE. One hundred years of immunotherapy: review of the first landmark studies. Allergy Asthma Proc. 33(2), 122–128 (2012).
   Google Scholar
• Van Metre TE Jr, Adkinson NF Jr, Lichtenstein LM et al. A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J. Allergy Clin. Immunol. 65(4), 288–297 (1980).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. J. Allergy Clin. Immunol. 83(4), 797–802 (1989).
   PubMed Web of Science ®Google Scholar
• Francis JN, Durham SR. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr. Opin. Allergy Clin. Immunol. 4(6), 543–548 (2004).
   PubMedGoogle Scholar
• Moingeon P, Lombardi V, Saint-Lu N, Tourdot S, Bodo V, Mascarell L. Adjuvants and vector systems for allergy vaccines. Immunol. Allergy Clin. North Am. 31(2), 407–419, xii (2011).
   PubMedGoogle Scholar
• Clapp T, Siebert P, Chen D, Jones Braun L. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. J. Pharm. Sci. 100(2), 388–401 (2011).
   PubMed Web of Science ®Google Scholar
• Clements CJ, Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 20(Suppl. 3), S24–S33 (2002).
   PubMed Web of Science ®Google Scholar
• Wilcock LK, Francis JN, Durham SR. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin. Exp. Allergy 34(9), 1373–1378 (2004).
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198), 1122–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Gupta RK. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32(3), 155–172 (1998).
   PubMed Web of Science ®Google Scholar
• Bergfors E, Trollfors B, Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine 22(1), 64–69 (2003).
   PubMed Web of Science ®Google Scholar
• Bergfors E, Björkelund C, Trollfors B. Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines. Eur. J. Pediatr. 164(11), 691–697 (2005).
   PubMed Web of Science ®Google Scholar
• Brito LA, Chan M, Baudner B et al. An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine 29(37), 6262–6268 (2011).
   PubMed Web of Science ®Google Scholar
• Aguilar JC, Rodríguez EG. Vaccine adjuvants revisited. Vaccine 25(19), 3752–3762 (2007).
   PubMed Web of Science ®Google Scholar
• Shah NM, Mangat GK, Balakrishnan C, Buch VI, Joshi VR. Accidental self-injection with Freund’s complete adjuvant. J. Assoc. Physicians India 49, 366–368 (2001).
   Google Scholar
• Sano K, Haneda K, Tamura G, Shirato K. Ovalbumin (OVA) and Mycobacterium tuberculosis bacilli cooperatively polarize anti-OVA T-helper (Th) cells toward a Th1-dominant phenotype and ameliorate murine tracheal eosinophilia. Am. J. Respir. Cell Mol. Biol. 20(6), 1260–1267 (1999).
   Google Scholar
• Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R. Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. Influenza Other Respi. Viruses 5(5), 299–305 (2011).
   PubMed Web of Science ®Google Scholar
• Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum. Vaccin. 4(5), 347–349 (2008).
   PubMed Web of Science ®Google Scholar
• Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 60(5), 678–684 (2005).
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Williams A, Colegio OR et al. NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells. Nature 484(7395), 510–513 (2012).
   PubMedGoogle Scholar
• Musarra A, Bignardi D, Troise C, Passalacqua G. Long-lasting effect of a monophosphoryl lipid-adjuvanted immunotherapy to Parietaria. A controlled field study. Eur. Ann. Allergy Clin. Immunol. 42(3), 115–119 (2010).
   PubMedGoogle Scholar
• Gawchik SM, Saccar CL. Pollinex Quattro Tree: allergy vaccine. Expert Opin. Biol. Ther. 9(3), 377–382 (2009).
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol. Immunopathol. (Madr.) 31(5), 270–277 (2003).
   PubMedGoogle Scholar
• Rosewich M, Schulze J, Fischer von Weikersthal-Drachenberg KJ, Zielen S. Ultra-short course immunotherapy in children and adolescents during a 3-yrs post-marketing surveillance study. Pediatr. Allergy Immunol. 21(1 Pt 2), e185–e189 (2010).
   PubMed Web of Science ®Google Scholar
• McCormack PL, Wagstaff AJ. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs 66(7), 931–938 (2006).
   PubMed Web of Science ®Google Scholar
• Kersten GF, Crommelin DJ. Liposomes and ISCOMs. Vaccine 21(9–10), 915–920 (2003).
   PubMed Web of Science ®Google Scholar
• McWilliam AS, Stewart GA. Production of multilamellar, small unilamellar and reverse-phase liposomes containing house dust mite allergens. Potential adjuvants in the immunotherapy of allergic disease. J. Immunol. Methods 121(1), 53–60 (1989).
   Google Scholar
• Alvarez MJ, Echechipía S, García B et al. Liposome-entrapped D. pteronyssinus vaccination in mild asthma patients: effect of 1-year double-blind, placebo-controlled trial on inflammation, bronchial hyperresponsiveness and immediate and late bronchial responses to the allergen. Clin. Exp. Allergy 32(11), 1574–1582 (2002).
   Google Scholar
• Calderón L, Facenda E, Machado L et al. Modulation of the specific allergic response by mite allergens encapsulated into liposomes. Vaccine 24(Suppl. 2), S2–38 (2006).
   Google Scholar
• Lövgren K, Morein B. The requirement of lipids for the formation of immunostimulating complexes (ISCOMS). Biotechnol. Appl. Biochem. 10(2), 161–172 (1988).
   PubMed Web of Science ®Google Scholar
• Morein F, Bengtsson KL. Functional aspects of ISCOMS. Immunol. Cell Biol. 76(4), 295–299 (1998).
   PubMed Web of Science ®Google Scholar
• Wilson NS, Yang B, Morelli AB et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol. Cell Biol. 90(5), 540–552 (2012).
   PubMed Web of Science ®Google Scholar
• Lövgren Bengtsson K, Morein B, Osterhaus AD. ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation. Expert Rev. Vaccines 10(4), 401–403 (2011).
   PubMed Web of Science ®Google Scholar
• Kensil CR. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 13(1-2), 1–55 (1996).
   PubMed Web of Science ®Google Scholar
• Rajput ZI, Hu SH, Xiao CW, Arijo AG. Adjuvant effects of saponins on animal immune responses. J. Zhejiang Univ. Sci. B 8(3), 153–161 (2007).
   PubMedGoogle Scholar
• Sun H, Chen L, Wang J, Wang K, Zhou J. Structure-function relationship of the saponins from the roots of Platycodon grandiflorum for hemolytic and adjuvant activity. Int. Immunopharmacol. 11(12), 2047–2056 (2011).
   Google Scholar
• Gupta GK, Agrawal DK. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma. BioDrugs 24(4), 225–235 (2010).
   PubMed Web of Science ®Google Scholar
• Jain VV, Kitagaki K, Businga T et al. CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J. Allergy Clin. Immunol. 110(6), 867–872 (2002).
   PubMed Web of Science ®Google Scholar
• Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv. Drug Deliv. Rev. 61(3), 256–262 (2009).
   PubMed Web of Science ®Google Scholar
• Nayak AS, Tripathy I, Levitt D. Novel Amb a 1 CpG oligodeoxyribonucleotide conjugate Ragweed vaccine administered to children. J. Allergy Clin. Immunol. 117(Suppl. 2), S159 (2006).
   Web of Science ®Google Scholar
• Pesce I, Monaci E, Muzzi A et al. Intranasal administration of CpG induces a rapid and transient cytokine response followed by dendritic and natural killer cell activation and recruitment in the mouse lung. J. Innate Immun. 2(2), 144–159 (2010).
   PubMedGoogle Scholar
• Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60(8), 915–928 (2008).
   PubMed Web of Science ®Google Scholar
• Wang W, Singh M. Selection of adjuvants for enhanced vaccine potency. World J. Vaccine. 1(2), 33–78 (2011).
   Google Scholar
• Broos S, Lundberg K, Akagi T et al. Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: implications for specific immunotherapy. Vaccine 28(31), 5075–5085 (2010).
   PubMed Web of Science ®Google Scholar
• Gómez S, Gamazo C, Roman BS, Ferrer M, Sanz ML, Irache JM. Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens. Vaccine 25(29), 5263–5271 (2007).
   PubMed Web of Science ®Google Scholar
• Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J. Pharm. Sci. 96(3), 473–483 (2007).
   PubMed Web of Science ®Google Scholar
• Balicer RD, Grotto I, Mimouni M, Mimouni D. Is childhood vaccination associated with asthma? A meta-analysis of observational studies. Pediatrics 120(5), e1269–e1277 (2007).
   Google Scholar
• Bilenki L, Gao X, Wang S et al. Dendritic cells from mycobacteria-infected mice inhibits established allergic airway inflammatory responses to ragweed via IL-10- and IL-12-secreting mechanisms. J. Immunol. 184(12), 7288–7296 (2010).
   PubMedGoogle Scholar
• Yokoi T, Amakawa R, Tanijiri T et al. Mycobacterium bovis Bacillus Calmette–Guérin suppresses inflammatory Th2 responses by inducing functional alteration of TSLP-activated dendritic cells. Int. Immunol. 20(10), 1321–1329 (2008).
   PubMed Web of Science ®Google Scholar
• Major T, Wohlleben G, Reibetanz B, Erb KJ. Application of heat killed Mycobacterium bovis-BCG into the lung inhibits the development of allergen-induced Th2 responses. Vaccine 20(11–12), 1532–1540 (2002).
   Google Scholar
• Arikan C, Bahceciler NN, Deniz G et al. Bacillus Calmette–Guérin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin. Exp. Allergy 34(3), 398–405 (2004).
   PubMed Web of Science ®Google Scholar
• Cohon A, Arruda LK, Martins MA, Guilherme L, Kalil J. Evaluation of BCG administration as an adjuvant to specific immunotherapy in asthmatic children with mite allergy. J. Allergy Clin. Immunol. 120(1), 210–213 (2007).
   Google Scholar
• Ou-Yang HF, Hu XB, Ti XY et al. Suppression of allergic airway inflammation in a mouse model by Der p2 recombined BCG. Immunology 128(Suppl. 1), e343–e352 (2009).
   Google Scholar
• Coudeyras S, Forestier C. Microbiota and probiotics: effects on human health. Can. J. Microbiol. 56(8), 611–650 (2010).
   PubMed Web of Science ®Google Scholar
• Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J. Allergy Clin. Immunol. 108(4), 516–520 (2001).
   PubMed Web of Science ®Google Scholar
• Ouwehand A, Isolauri E, Salminen S. The role of the intestinal microflora for the development of the immune system in early childhood. Eur. J. Nutr. 41(Suppl. 1), I32–I37 (2002).
   Google Scholar
• Ghadimi D, Fölster-Holst R, de Vrese M, Winkler P, Heller KJ, Schrezenmeir J. Effects of probiotic bacteria and their genomic DNA on Th1/Th2-cytokine production by peripheral blood mononuclear cells (PBMCs) of healthy and allergic subjects. Immunobiology 213(8), 677–692 (2008).
   PubMed Web of Science ®Google Scholar
• Giovannini M, Agostoni C, Riva E et al.; Felicita Study Group. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr. Res. 62(2), 215–220 (2007).
   PubMed Web of Science ®Google Scholar
• Stockert K, Schneider B, Porenta G, Rath R, Nissel H, Eichler I. Laser acupuncture and probiotics in school age children with asthma: a randomized, placebo-controlled pilot study of therapy guided by principles of traditional Chinese medicine. Pediatr. Allergy Immunol. 18(2), 160–166 (2007).
   PubMed Web of Science ®Google Scholar
• Rose MA, Stieglitz F, Köksal A, Schubert R, Schulze J, Zielen S. Efficacy of probiotic Lactobacillus GG on allergic sensitization and asthma in infants at risk. Clin. Exp. Allergy 40(9), 1398–1405 (2010).
   PubMed Web of Science ®Google Scholar
• Van Overtvelt L, Moussu H, Horiot S et al. Lactic acid bacteria as adjuvants for sublingual allergy vaccines. Vaccine 28(17), 2986–2992 (2010).
   PubMed Web of Science ®Google Scholar
• Cromwell O, Niederberger V, Horak F, Fiebig H. Clinical experience with recombinant molecules for allergy vaccination. Curr. Top. Microbiol. Immunol. 352, 27–42 (2011).
   PubMed Web of Science ®Google Scholar
• Valenta R, Linhart B, Swoboda I, Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 66(6), 775–783 (2011).
   PubMed Web of Science ®Google Scholar
• Wild C, Wallner M, Hufnagl K et al. A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities. Allergy 62(1), 33–41 (2007).
   PubMed Web of Science ®Google Scholar
• Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 116(3), 608–613 (2005).
   PubMed Web of Science ®Google Scholar
• Moldaver D, Larché M. Immunotherapy with peptides. Allergy 66(6), 784–791 (2011).
   PubMed Web of Science ®Google Scholar
• Boyce JA, Bochner B, Finkelman FD, Rothenberg ME. Advances in mechanisms of asthma, allergy, and immunology in 2011. J. Allergy Clin. Immunol. 129(2), 335–341 (2012).
   Google Scholar
• Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6(10), 761–771 (2006).
   PubMed Web of Science ®Google Scholar
• Walker C, Zuany-Amorim C. New trends in immunotherapy to prevent atopic diseases. Trends Pharmacol. Sci. 22(2), 84–90 (2001).
   Google Scholar
• Kopp MV, Brauburger J, Riedinger F et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 110(5), 728–735 (2002).
   PubMed Web of Science ®Google Scholar
• Massanari M, Nelson H, Casale T et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J. Allergy Clin. Immunol. 125(2), 383–389 (2010).
   PubMed Web of Science ®Google Scholar
• Majak P, Rychlik B, Pulaski L et al. Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma. J. Allergy Clin. Immunol. 125(6), 1220–1227 (2010).
   Google Scholar
• Niggemann B, Jacobsen L, Dreborg S et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 61(7), 855–859 (2006).
   PubMed Web of Science ®Google Scholar
• Möller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109(2), 251–256 (2002).
   PubMed Web of Science ®Google Scholar
• Holt PG, Strickland DH. Interactions between innate and adaptive immunity in asthma pathogenesis: new perspectives from studies on acute exacerbations. J. Allergy Clin. Immunol. 125(5), 963–972; quiz 973 (2010).
   PubMedGoogle Scholar
• Esch RE. Specific immunotherapy in the USA: general concept and recent initiatives. Arb. Paul Ehrlich Inst. Bundesamt. Sera Impfstoffe. Frankf. A. M. 94, 17–22; discussion 23 (2003).
   Google Scholar
• Senti G, Crameri R, Kuster D et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J. Allergy Clin. Immunol. 129(5), 1290–1296 (2012).
   PubMed Web of Science ®Google Scholar
• Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J. Allergy Clin. Immunol. 117(2), 263–268 (2006).
   PubMed Web of Science ®Google Scholar
• Marcucci F, Sensi L, Di Cara G et al. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr. Allergy Immunol. 16(6), 519–526 (2005).
   PubMed Web of Science ®Google Scholar
• Bernardini R, Campodonico P, Burastero S et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study. Curr. Med. Res. Opin. 22(8), 1515–1522 (2006).
   PubMed Web of Science ®Google Scholar